Nicox

Nicox company information, Employees & Contact Information

Explore related pages

Related company profiles:

Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com

Company Details

Employees
47
Founded
-
Address
Drakkar 2 - Bât D, 2405 Route Des Dolines - Cs 10313 - Sophia Antipolis,italy
Phone
33 4 97 24 53 00
Email
ni****@****cox.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
nicox.com
HQ
Valbonne
Looking for a particular Nicox employee's phone or email?

Nicox Questions

News

Nicox Provides First Half 2025 Financial Results - Yahoo! Finance UK

Nicox Provides First Half 2025 Financial Results Yahoo! Finance UK

Nicox Extends Existing Flexible Equity Financing - Yahoo Finance

Nicox Extends Existing Flexible Equity Financing Yahoo Finance

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories - Yahoo Finance

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories Yahoo Finance

Nicox Announces Shareholder Q&A Webpage Available - GlobeNewswire

Nicox Announces Shareholder Q&A Webpage Available GlobeNewswire

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients - Ophthalmology Times

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients Ophthalmology Times

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 - GlobeNewswire

Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 GlobeNewswire

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed - Yahoo! Finance Australia

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Yahoo! Finance Australia

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops - Ophthalmology Times

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops Ophthalmology Times

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients - GlobeNewswire

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients GlobeNewswire

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension - Ophthalmology Times

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension Ophthalmology Times

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470 - Ophthalmology Times

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470 Ophthalmology Times

Kowa initiates phase 3 safety trial of NCX 470 in Japan - Ophthalmology Times

Kowa initiates phase 3 safety trial of NCX 470 in Japan Ophthalmology Times

Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA® - Yahoo Finance

Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA® Yahoo Finance

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan - GlobeNewswire

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan GlobeNewswire

Nicox Announces First Commercial Sale of ZERVIATE in China - GlobeNewswire

Nicox Announces First Commercial Sale of ZERVIATE in China GlobeNewswire

Nicox and Soleus Sign $16.5 million Royalty and Equity Financing - GlobeNewswire

Nicox and Soleus Sign $16.5 million Royalty and Equity Financing GlobeNewswire

Kowa secures expanded rights to Nicox's glaucoma drug in key markets - FirstWord Pharma

Kowa secures expanded rights to Nicox's glaucoma drug in key markets FirstWord Pharma

Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop - Eyes On Eyecare

Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop Eyes On Eyecare

Nicox Projects Full Debt Repayment By 2026 - Nasdaq

Nicox Projects Full Debt Repayment By 2026 Nasdaq

Nicox eyes US, China filings after glaucoma eye drop scores second Phase III win - FirstWord Pharma

Nicox eyes US, China filings after glaucoma eye drop scores second Phase III win FirstWord Pharma

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma - Yahoo Finance

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Yahoo Finance

Nicox publishes results of Phase 3 trial of NCX 470 for treatment of glaucoma - Ophthalmology Times

Nicox publishes results of Phase 3 trial of NCX 470 for treatment of glaucoma Ophthalmology Times

Nicox’ NCX 470 demonstrates sustained efficacy - The Pharma Letter

Nicox’ NCX 470 demonstrates sustained efficacy The Pharma Letter

Nicox, Kowa make a deal for glaucoma drug; French techbio raises €15M - Endpoints News

Nicox, Kowa make a deal for glaucoma drug; French techbio raises €15M Endpoints News

Nicox glaucoma drug meets requirements for US and China approvals - The Pharma Letter

Nicox glaucoma drug meets requirements for US and China approvals The Pharma Letter

Nicox S.A. (EPA:ALCOX): Are Analysts Optimistic? - simplywall.st

Nicox S.A. (EPA:ALCOX): Are Analysts Optimistic? simplywall.st

Nicox and Kowa sign €191.5 M deal for glaucoma treatment - BioSpectrum Asia

Nicox and Kowa sign €191.5 M deal for glaucoma treatment BioSpectrum Asia

With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus - Fierce Biotech

With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus Fierce Biotech

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries - GlobeNewswire

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries GlobeNewswire

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis - GlobeNewswire

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis GlobeNewswire

Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries - PR Newswire

Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries PR Newswire

Predicting the Future The Business Case for Forecasting - Pharma Voice

Predicting the Future The Business Case for Forecasting Pharma Voice

Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene™ AMD test in North America - PR Newswire

Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene™ AMD test in North America PR Newswire

Top Nicox Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant